Total submissions: 17
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000077267 | SCV000244426 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-08-10 | reviewed by expert panel | curation | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.000000101 |
Invitae | RCV001081276 | SCV000071906 | benign | Hereditary breast ovarian cancer syndrome | 2024-01-20 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001284557 | SCV000210569 | likely benign | not provided | 2021-05-05 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 24323938, 20104584, 20383589, 21218378, 21990134, 28678401, 21232165, 18559594, 23034506, 17924331, 27300552, 32444794, 32123317) |
Ambry Genetics | RCV000162545 | SCV000212949 | benign | Hereditary cancer-predisposing syndrome | 2014-11-19 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Counsyl | RCV000077267 | SCV000488588 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-05-03 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000162545 | SCV000683452 | likely benign | Hereditary cancer-predisposing syndrome | 2015-02-16 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000168552 | SCV000694568 | benign | not specified | 2019-12-23 | criteria provided, single submitter | clinical testing | Variant summary: BRCA2 c.1804G>A (p.Gly602Arg) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.2e-05 in 239200 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in BRCA2 causing Hereditary Breast and Ovarian Cancer (4.2e-05 vs 0.00075), allowing no conclusion about variant significance. c.1804G>A has been reported in the literature in individuals affected with Hereditary Breast and Ovarian Cancer (Lee_2008, Soegaard_2008, Borg_2010, Balabas_2010, Stegel_2011). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Co-occurrences with other pathogenic variant(s) have been reported (BRCA1 c.5263_5264insC, p.Ser1755?fs; BRCA1 c.2679_2682delGAAA, p.Lys893_Lys894?fs in the BIC database; BRCA2 c.7558C>T , p.Arg2520Ter in a patient tested at our laboratory), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as benign. |
Genome Diagnostics Laboratory, |
RCV000077267 | SCV000743266 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2017-07-28 | criteria provided, single submitter | clinical testing | |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000077267 | SCV000744418 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-09-21 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV001284557 | SCV001470405 | likely benign | not provided | 2022-12-24 | criteria provided, single submitter | clinical testing | |
Center for Genomic Medicine, |
RCV000168552 | SCV002550290 | benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Sharing Clinical Reports Project |
RCV000077267 | SCV000109064 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2010-01-15 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000077267 | SCV000145944 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2004-02-20 | no assertion criteria provided | clinical testing | |
Diagnostic Laboratory, |
RCV000077267 | SCV000733235 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | no assertion criteria provided | clinical testing | ||
Clinical Genetics Laboratory, |
RCV000168552 | SCV001906033 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000168552 | SCV001953400 | benign | not specified | no assertion criteria provided | clinical testing | ||
BRCAlab, |
RCV000077267 | SCV004244233 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2020-03-02 | no assertion criteria provided | clinical testing |